Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1952 1
1960 1
1961 3
1963 1
1964 3
1967 1
1969 2
1971 4
1972 1
1973 4
1974 5
1975 205
1976 251
1977 262
1978 258
1979 297
1980 344
1981 461
1982 537
1983 731
1984 943
1985 1078
1986 1093
1987 1200
1988 1250
1989 1366
1990 1567
1991 1708
1992 1747
1993 1898
1994 2025
1995 2056
1996 2124
1997 2252
1998 2356
1999 2476
2000 2634
2001 2775
2002 3012
2003 3379
2004 3591
2005 3876
2006 3483
2007 3614
2008 3905
2009 4323
2010 4733
2011 5198
2012 5737
2013 6107
2014 6734
2015 7198
2016 7229
2017 7302
2018 7623
2019 8082
2020 9111
2021 9692
2022 8971
2023 8610
2024 9279
2025 161

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158,986 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for regimens p
Search for Reginensi P instead (2 results)
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Rodriguez-Otero P, et al. N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10. N Engl J Med. 2023. PMID: 36762851 Clinical Trial.
At a median follow-up of 18.6 months, the median progression-free survival was 13.3 months in the ide-cel group, as compared with 4.4 months in the standard-regimen group (hazard ratio for disease progression or death, 0.49; 95% confidence interval, 0.38 to 0.65; P& …
At a median follow-up of 18.6 months, the median progression-free survival was 13.3 months in the ide-cel group, as compared with 4.4 months …
Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F, Bint Abdul Jabbar H, Malik H, Sadaf H, Sarfraz A, Sarfraz Z, Cherrez-Ojeda I. Latif F, et al. Expert Rev Anticancer Ther. 2022 Feb;22(2):229-235. doi: 10.1080/14737140.2022.2023011. Epub 2022 Jan 24. Expert Rev Anticancer Ther. 2022. PMID: 34949142

A positive effect size was found for PFS in the ITT arms (d = 1.55, P < 0.001). The atezolizumab plus chemotherapy group had a positive effect size for OS compared to control groups (d = 0.52, P < 0.001). ...However, there is a need to harmonize and explore bi

…

A positive effect size was found for PFS in the ITT arms (d = 1.55, P < 0.001). The atezolizumab plus chemotherapy group had a pos

…
The Two-Bag Method for Treatment of Diabetic Ketoacidosis in Adults.
Haas NL, Gianchandani RY, Gunnerson KJ, Bassin BS, Ganti A, Hapner C, Boyd C, Cranford JA, Whitmore SP. Haas NL, et al. J Emerg Med. 2018 May;54(5):593-599. doi: 10.1016/j.jemermed.2018.01.004. Epub 2018 Apr 5. J Emerg Med. 2018. PMID: 29628184

The 2B and 1B groups were similar in demographics and baseline metabolic derangements, though significantly more patients in the 2B group received care in a hybrid ED and intensive care unit setting (94.1% vs. 51.4%; p < 0.01). 2B patients experienced a shorter interval

…
The 2B and 1B groups were similar in demographics and baseline metabolic derangements, though significantly more patients in the 2B group re …
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.
Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. Shah MA, et al. Future Oncol. 2021 Apr;17(10):1143-1153. doi: 10.2217/fon-2020-0969. Epub 2021 Feb 3. Future Oncol. 2021. PMID: 33533655 Free PMC article. Clinical Trial.
Overall survival and event-free survival are the dual primary end points. Clinical trial registration: NCT04210115 (ClinicalTrials.gov)....
Overall survival and event-free survival are the dual primary end points. Clinical trial registration: NCT04210115 (ClinicalTrials.go …
Validation of stroke-specific protocols for the 10-meter walk test and 6-minute walk test conducted using 15-meter and 30-meter walkways.
Cheng DK, Nelson M, Brooks D, Salbach NM. Cheng DK, et al. Top Stroke Rehabil. 2020 May;27(4):251-261. doi: 10.1080/10749357.2019.1691815. Epub 2019 Nov 21. Top Stroke Rehabil. 2020. PMID: 31752634
Background: Stroke-specific protocols for the 10-meter and 6-minute walk tests that include instructions for people with aphasia, accessible walkway lengths, and allow provision of assistance to walk are needed to facilitate uptake in hospital settings.Objectives: To estim …
Background: Stroke-specific protocols for the 10-meter and 6-minute walk tests that include instructions for people with aphasia, acc …
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, Sandhu I, McCurdy A, Facon T, Mateos MV, Mian H. Ebraheem MS, et al. Blood Adv. 2024 Dec 10;8(23):5993-6002. doi: 10.1182/bloodadvances.2024014139. Blood Adv. 2024. PMID: 39348665 Free PMC article.
The objective of our study was to conduct a systematic review and meta-analysis to measure the efficacy and toxicity of quadruplet regimens used in NDMM. Embase, MEDLINE, Web of Science, Cochrane Library, clinical trial registries, and meeting libraries from incepti …
The objective of our study was to conduct a systematic review and meta-analysis to measure the efficacy and toxicity of quadruplet regime …
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Panés J, Colombel JF, D'Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Hibi T, Watanabe M, Lefebvre J, Finney-Hayward T, Sanchez Gonzalez Y, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ. Panés J, et al. Gastroenterology. 2022 Jun;162(7):1891-1910. doi: 10.1053/j.gastro.2022.02.033. Epub 2022 Feb 25. Gastroenterology. 2022. PMID: 35227777 Free article. Clinical Trial.
At week 8, all patients were rerandomized 2:2:1 (main study) to 40 mg every week (ew), 40 mg every other week (eow), or exploratory therapeutic drug monitoring; or 1:1 (Japan substudy) to 40 mg ew or 40 mg eow maintenance regimens. RESULTS: In the main study, 13.3% vs 10.9 …
At week 8, all patients were rerandomized 2:2:1 (main study) to 40 mg every week (ew), 40 mg every other week (eow), or exploratory therapeu …
Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
Liu GF, Li GJ, Zhao H. Liu GF, et al. J Cell Biochem. 2018 Jan;119(1):511-523. doi: 10.1002/jcb.26210. Epub 2017 Jul 17. J Cell Biochem. 2018. PMID: 28608558 Review.
Higher overall response rate (ORR) was observed in patients treated with the gemcitabine + S-1 and FOLFIRINO regimens. Thrombocytopenia reduced in patients treated with the S-1 regimen. The Gemcitabine + S-1 and FOLFIRINO regimens had better short- and long-t …
Higher overall response rate (ORR) was observed in patients treated with the gemcitabine + S-1 and FOLFIRINO regimens. Thrombocytopen …
Prospective, randomized study comparing two different regimens of split-dose polyethylene glycol and their effect on endoscopic outcomes.
Abou Zeid J, Hallit S, Akiki B, Abou Zeid Z, Yazbeck C. Abou Zeid J, et al. BMC Gastroenterol. 2024 Apr 12;24(1):132. doi: 10.1186/s12876-024-03212-z. BMC Gastroenterol. 2024. PMID: 38609900 Free PMC article. Clinical Trial.
BACKGROUND: Different split regimens of polyethylene glycol are routinely used and no guidelines are available to select an optimal protocol of ingestion. ...CONCLUSION: While both (2 + 2) and (3 + 1) regimens of polyethylene glycol are a good choice for a successfu …
BACKGROUND: Different split regimens of polyethylene glycol are routinely used and no guidelines are available to select an optimal p …
158,986 results
You have reached the last available page of results. Please see the User Guide for more information.